

Myriam Labopin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9342852/publications.pdf>

Version: 2024-02-01

219
papers

10,338
citations

36271

51
h-index

46771

89
g-index

223
all docs

223
docs citations

223
times ranked

6916
citing authors

#	ARTICLE	IF	CITATIONS
1	Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party. <i>Journal of Clinical Oncology</i> , 2007, 25, 4938-4945.	0.8	446
2	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). <i>Leukemia</i> , 2005, 19, 2304-2312.	3.3	417
3	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. <i>Blood</i> , 2017, 129, 1548-1556.	0.6	340
4	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. <i>Blood</i> , 2008, 112, 3574-3581.	0.6	261
5	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2012, 119, 1599-1606.	0.6	254
6	Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 735-741.	0.8	251
7	Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4570-4577.	0.8	238
8	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
9	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
10	Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP/EBMT analysis on patients with AML in remission. <i>Bone Marrow Transplantation</i> , 2016, 51, 610-611.	1.3	212
11	CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2013, 122, 3359-3364.	0.6	202
12	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	3.3	199
13	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. <i>Leukemia</i> , 2012, 26, 2462-2468.	3.3	170
14	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	2.5	151
15	Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 3549-3556.	0.8	143
16	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	2.2	140
17	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 392-399.	1.7	139
18	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. <i>Cancer</i> , 2018, 124, 1428-1437.	2.0	131

#	ARTICLE	IF	CITATIONS
19	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (IACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 283-306.	1.3	128
20	Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2012, 26, 1211-1217.	3.3	126
21	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3144-3151.	0.8	119
22	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	0.6	110
23	Post-transplant cyclophosphamide <i>versus</i> anti-thymocyte globulin as graft- <i>versus</i> -host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	1.7	109
24	Anti-thymocyte globulin as graft- <i>versus</i> -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 224-234.	1.7	108
25	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	3.4	97
26	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	1.3	97
27	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014, 28, 779-786.	3.3	95
28	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	0.6	93
29	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 389-396.	1.3	92
30	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 1142-1152.	2.0	91
31	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 139-149.	1.7	88
32	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. <i>Leukemia</i> , 2016, 30, 447-455.	3.3	85
33	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 1317-1328.	1.7	84
34	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	1.2	82
35	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2015, 121, 1048-1055.	2.0	77
36	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	2.5	76

#	ARTICLE	IF	CITATIONS
37	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 1815-1826.	1.3	75
38	Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2014, 120, 2760-2765.	2.0	73
39	A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 24.	6.9	70
40	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	3.7	70
41	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 351-357.	1.3	68
42	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	6.9	68
43	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 1810-1822.	1.7	64
44	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. <i>British Journal of Haematology</i> , 2000, 111, 1130-1137.	1.2	63
45	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
46	Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Cancer</i> , 2014, 50, 411-417.	1.3	60
47	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 113.	6.9	60
48	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1013-1021.	2.0	59
49	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 25.	6.9	57
50	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. <i>Haematologica</i> , 2021, 106, 375-383.	1.7	57
51	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , 2015, 21, 189-197.	1.4	56
52	Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 461-469.	1.3	55
53	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 519-530.	1.3	54
54	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 489-495.	2.0	53

#	ARTICLE	IF	CITATIONS
55	High CD34+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia – an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	0.8	53
56	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2018, 93, 246-253.	2.0	52
57	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	6.9	51
58	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 53.	6.9	51
59	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2016, 9, 118.	6.9	50
60	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014, 99, 1509-1515.	1.7	48
61	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	3.3	48
62	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <i>JACC: CardioOncology</i> , 2021, 3, 250-259.	1.7	48
63	Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. <i>Bone Marrow Transplantation</i> , 2015, 50, 45-50.	1.3	47
64	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , 2015, 2, e384-e392.	2.2	46
65	Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , 2019, 104, e398-e401.	1.7	46
66	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <i>Clinical Hematology International</i> , 2019, 1, 58.	0.7	46
67	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. <i>Bone Marrow Transplantation</i> , 2015, 50, 1495-1502.	1.3	44
68	Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. <i>Bone Marrow Transplantation</i> , 2016, 51, 186-193.	1.3	44
69	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
70	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). <i>Leukemia</i> , 2015, 29, 2375-2381.	3.3	43
71	Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 3410 years. <i>Bone Marrow Transplantation</i> , 2015, 50, 1508-1512.	1.3	43
72	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2017, 10, 20.	6.9	43

#	ARTICLE	IF	CITATIONS
73	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 184-191.	1.7	43
74	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1786-1791.	2.0	42
75	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group—an observational analysis by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2015, 50, 1063-1068.	1.3	41
76	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	0.8	40
77	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 1066-1074.	1.7	40
78	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018, 96, 73-81.	1.3	40
79	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	2.0	40
80	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020, 26, 6475-6482.	3.2	40
81	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 26.	2.8	40
82	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , 2018, 9, 3379-3393.	0.8	40
83	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 88.	2.8	39
84	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	2.5	39
85	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 130.	6.9	38
86	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 278-284.	2.0	38
87	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2017, 123, 2671-2679.	2.0	37
88	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	1.3	37
89	Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. <i>Blood</i> , 2010, 116, 122-128.	0.6	36
90	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 683-689.	1.7	36

#	ARTICLE	IF	CITATIONS
91	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. <i>Leukemia</i> , 2019, 33, 230-239.	3.3	36
92	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	1.3	36
93	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	1.3	36
94	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , 2016, 9, 89.	6.9	35
95	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	1.7	35
96	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , 2018, 2, 1180-1186.	2.5	35
97	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP-EBMT analysis. <i>Journal of Internal Medicine</i> , 2019, 285, 407-418.	2.7	35
98	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 997-1003.	2.0	34
99	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	2.5	34
100	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1499-1510.	1.3	34
101	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission: Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2017, 123, 824-831.	2.0	32
102	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. <i>Clinical Cancer Research</i> , 2018, 24, 2794-2803.	3.2	32
103	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	1.3	32
104	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	2.0	31
105	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017, 123, 1965-1970.	2.0	31
106	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 186, 767-776.	1.2	31
107	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015, 100, 558-564.	1.7	29
108	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1097-1103.	0.6	29

#	ARTICLE	IF	CITATIONS
109	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 1591-1598.	1.7	29
110	Reducedâ€toxicity conditioning with fludarabine, onceâ€daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. <i>Cancer</i> , 2015, 121, 562-569.	2.0	28
111	Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1471-1475.	2.0	28
112	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 859-866.	2.0	28
113	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing Tâ€cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (<sc>ALWP</sc>) of the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2018, 183, 411-420.	1.2	27
114	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1493-1508.	1.3	27
115	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	6.9	27
116	Sequential chemotherapy followed by reducedâ€intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of <sc>EBMT</sc>. <i>British Journal of Haematology</i> , 2017, 176, 431-439.	1.2	26
117	Occurrence of graftâ€versusâ€host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <i>Journal of Internal Medicine</i> , 2018, 283, 178-189.	2.7	26
118	Postâ€transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLAâ€identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 209-218.	2.0	26
119	Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWPO1 trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 978-983.	1.3	25
120	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Annals of Hematology</i> , 2019, 98, 2389-2398.	0.8	24
121	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1915-1922.	2.0	24
122	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1944-1952.	3.3	23
123	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. <i>American Journal of Hematology</i> , 2018, 93, 769-777.	2.0	22
124	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	6.9	22
125	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <i>Oncotarget</i> , 2017, 8, 112972-112979.	0.8	22
126	Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. <i>American Journal of Hematology</i> , 2017, 92, 1318-1323.	2.0	21

#	ARTICLE	IF	CITATIONS
127	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 128.	6.9	21
128	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€TD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 736-744.	2.0	21
129	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Phâ€negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 778-785.	2.0	21
130	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 653-659.	2.0	18
131	Allogeneic stem cell transplantation benefits for patients â%¥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	1.7	18
132	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 1272-1280.	1.3	18
133	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50Âyearsâ”a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , 2016, 9, 65.	6.9	17
134	Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis. <i>Transfusion</i> , 2016, 56, 2021-2029.	0.8	17
135	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 789-796.	2.0	17
136	Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 595-602.	1.3	17
137	FLAMISA-Based Reduced-intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2165-2173.	2.0	17
138	Second allogeneic haematopoietic cell transplantation using HLAâ€matched unrelated <i>versus</i> Tâ€cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	1.2	17
139	Additional cytogenetic features determine outcome in patients allografted for <i>TP53</i> mutant acute myeloid leukemia. <i>Cancer</i> , 2022, 128, 2922-2931.	2.0	17
140	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2251-2260.	2.0	16
141	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 763-772.	1.3	16
142	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); <i>DEKâ€NUP214</i> shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	1.2	16
143	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantationâ”a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 1190-1199.	1.3	16
144	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	1.3	16

#	ARTICLE	IF	CITATIONS
145	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
146	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 4258-4266.	3.2	15
147	Myeloablative Chemo-Conditioning for First Hematopoietic STEM CELL Transplantation in Children with ACUTE Lymphoblastic Leukemia in First or Second Remission. <i>Blood</i> , 2014, 124, 546-546.	0.6	14
148	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	1.3	13
149	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	0.6	13
150	Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory. <i>American Journal of Hematology</i> , 2018, 93, 794-802.	2.0	12
151	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020, 34, 1144-1153.	3.3	12
152	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1057-1065.	2.0	12
153	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	3.2	12
154	Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2009, 44, 589-594.	1.3	11
155	Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia?. <i>Transplantation</i> , 2014, 98, 569-577.	0.5	11
156	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2454-2463.	1.3	11
157	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 3359-3359.	0.6	11
158	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 377-382.	0.2	10
159	Total body irradiation + fludarabine compared to busulfan + fludarabine as reduced-toxicity conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	1.3	10
160	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	1.3	10
161	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. <i>Bone Marrow Transplantation</i> , 2022, 57, 384-390.	1.3	10
162	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	1.3	9

#	ARTICLE	IF	CITATIONS
163	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 171.e1-171.e8.	0.6	9
164	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 399-406.	1.3	9
165	A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. <i>Bone Marrow Transplantation</i> , 2014, 49, 376-381.	1.3	8
166	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1878-1882.	3.3	8
167	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 917-927.	1.3	8
168	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2022, 57, 1556-1563.	1.3	8
169	Allogeneic stem cell transplant in patients with acute myeloid leukemia and Karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , 2021, 10, 23-33.	1.3	7
170	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2820-2825.	1.3	7
171	Phase II Prospective Multicentre Study Testing The Efficacy and Safety Of a Clofarabine (Clo), I.v. Busulfan (Bu) and Antithymocyte Globulins (ATG)-Based Reduced-Intensity Conditioning Regimen (RIC) Before Allogeneic Stem Cell Transplantation (allo-SCT) For High-Risk Myelodysplastic Syndrome Or Acute Leukemia: The Cloric Trial. <i>Blood</i> , 2013, 122, 413-413.	0.6	7
172	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 1068-1080.	1.3	7
173	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1421-1427.	1.3	7
174	Investigating covariate-by-centre interaction in survival data. <i>Statistical Methods in Medical Research</i> , 2018, 27, 920-932.	0.7	6
175	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	3.3	6
176	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2445-2453.	1.3	6
177	Comparison of fludarabine+melfalan and fludarabine+treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	1.3	6
178	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2014, 49, 950-954.	1.3	5
179	Hematopoietic cell transplant nurse coordinators' perceptions of related donor care: a European survey from the EBMT Nurses Group. <i>Bone Marrow Transplantation</i> , 2020, 55, 623-632.	1.3	5
180	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 296-304.	0.2	5

#	ARTICLE	IF	CITATIONS
181	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-787.	1.3	5
182	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	1.3	5
183	Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. <i>Leukemia</i> , 1992, 6 Suppl 4, 95-9.	3.3	5
184	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	1.3	5
185	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2â€‰%Gy) as conditioning prior to allogeneic stem cell transplantation in patients (â‰¥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 729-739.	1.3	4
186	Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo Osseo. <i>Nutrition</i> , 2020, 79-80, 110998.	1.1	4
187	Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 614-621.	1.3	4
188	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1077-1085.	1.3	4
189	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1842-1849.	1.3	4
190	Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 380-388.	0.6	4
191	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	1.3	4
192	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia â€” a study of the Acute Leukemia Working Party of the EBMT. <i>Leukemia and Lymphoma</i> , 2021, 62, 399-409.	0.6	3
193	Cytogenetic risk classification maintains its prognostic significance in transplanted <i>FLT3â€‰TD</i> mutated acute myeloid leukemia patients: On behalf of the <scp>acute leukemia working party</scp>/<scp>European society of blood and marrow transplantation</scp>. <i>American Journal of Hematology</i> . 2022. 97. 274-282.	2.0	3
194	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	1.2	3
195	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1047-1055.	1.3	2
196	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 461-469.	1.3	2
197	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 399-399.	0.6	2
198	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	1.3	1

#	ARTICLE	IF	CITATIONS
199	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 831-840.	0.2	1
200	Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems. <i>Blood</i> , 2012, 120, 734-734.	0.6	1
201	Different Approaches Of Allogeneic Stem Cell Transplantation For Acute Leukemias In Suzhou (China) Lead To Similar Outcome Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis. <i>Blood</i> , 2013, 122, 2131-2131.	0.6	1
202	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 1230-1230.	0.6	1
203	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. <i>ESMO Open</i> , 2020, 5, e000860.	2.0	1
204	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	1.3	1
205	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 0, ...	1.3	1
206	Reply to F. Ferrara et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e248-e249.	0.8	0
207	Study of V617F JAK2-Positive and JAK2-Negative Patients within 18 Families with Myeloproliferative Disorders (MPD): Disease Characteristics and Evolution, EPOR and MPL Analysis.. <i>Blood</i> , 2006, 108, 672-672.	0.6	0
208	Long-Term Follow-up of 94 Families with Myeloproliferative Neoplasms: Implications of the V617F JAK2 mutation, Life Expectancy and Complication Rates. <i>Blood</i> , 2010, 116, 1978-1978.	0.6	0
209	Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT). <i>Blood</i> , 2013, 122, 3334-3334.	0.6	0
210	Similar Outcome Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning in Children: A Retrospective Study from the SFGM-TC. <i>Blood</i> , 2014, 124, 2551-2551.	0.6	0
211	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014, 124, 681-681.	0.6	0
212	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014, 124, 1227-1227.	0.6	0
213	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2017, 130, 852-852.	0.6	0
214	Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 1840-1840.	0.6	0
215	Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2021, 138, 3916-3916.	0.6	0
216	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Transplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020, 136, 26-27.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2020, 136, 6-7.	0.6	0
218	Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT. Blood, 2020, 136, 5-6.	0.6	0
219	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplantation, 2022, , .	1.3	0